Head-to-head evidence
HRS-7535 vs HSK7653
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
HRS-7535
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06672172 · Phase 3 · completed
This is a well-designed randomized, double-blind, placebo-controlled trial with a recognized clinical measure (HbA1c change) as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
HSK7653
Developed by Haisco Pharmaceutical Group
NCT04556851 · Phase 3 · completed
This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-7535's landscape · HSK7653's landscape